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ABSTRACT
This study evaluated the accuracy of cefotetan
susceptibility determination using the MicroScan
WalkAway system for AmpC-producing Klebsiella
pneumoniae. In total, 57 K. pneumoniae isolates that
showed a D-shape flattening in a double-disk
synergy test were studied. Cefotetan MICs were
determined by the agar dilution method. The
blaDHA gene was detected in all 57 isolates, one of
which co-harboured blaCMY-1. According to the
MicroScan system, 28 isolates were susceptible, 18
were intermediately-resistant, and 11 were resist-
ant to cefotetan. Compared with the agar dilution
method, very major, minor and major error rates
were 28.1% (16 ⁄ 57), 47.4% (27 ⁄ 57) and 1.8%
(1 ⁄ 57), respectively.
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Although the production of AmpC-type b-lacta-
mase is one of the predominant mechanisms
causing resistance to b-lactam antibiotics in most
Gram-negative bacilli [1], Klebsiella spp. generally
lack a chromosomal AmpC b-lactamase [2]. How-
ever, Klebsiella pneumoniae isolates producing a
plasmid-mediated AmpC-type b-lactamase
(PABL) were first reported in Korea in 1989 [3]
and have become more frequent (especially the
DHA type in Korea) [4,5]. These organisms have
been involved in several outbreaks of infection,
and treatment failures can occur if isolates pro-
ducing PABL appear falsely susceptible in vitro
[2]. Therefore, detection of PABL producers and
correct reporting of susceptibility test results are
very important for effective therapy and infection
control purposes.
For the accurate detection of PABL, it is import-
ant to detect isolates that are insusceptible to the
cephamycins, and then to distinguish between
PABL producers and those with decreased outer-
membrane permeability [2]. However, some
PABL-producing K. pneumoniae isolates were
found to be reported as cefotetan-susceptible by
the MicroScan WalkAway system (Dade Behring,
West Sacramento, CA, USA), using the Neg
Combo Panel Type 32. The present study was
performed to evaluate the extent of this problem.
In total, 57 K. pneumoniae isolates were collected
from Kangham St Mary’s hospital, Seoul, Korea,
between December 2004 and July 2005. These
isolates were positive for extended-spectrum
b-lactamases (ESBLs) according to the MicroScan
system, and showed a D-shape flattening of the
inhibition zone around the oxyimino-cephalosp-
orin disk adjacent to the amoxycillin–clavulanate
disk in double-disk synergy tests. These were
performed by placing 30-lg disks of cefotaxime,
ceftazidime, cefepime and aztreonam at a dis-
tance of 20 mm (centre-to-centre) from a disk
containing an amoxycillin–clavulanate disk
(20 ⁄ 10 lg) [6]. MICs of cefotetan and cefoxitin
for the 57 isolates were determined by the
standard agar dilution method according to CLSI
(formerly NCCLS) guidelines [7]. The possibility
of an inoculum effect was examined for isolates
that produced PABL but that were susceptible to
cefotetan according to agar dilution; this was
done using inocula of c. 104 and 106 CFU ⁄mL,
and was defined by an eight-fold or greater
increase in MIC with the higher inoculum.
Total DNA was extracted from the 57 K. pneu-
moniae isolates by heating at 95C for 10 min. For
PABL detection, multiplex PCR was performed as
described by Perez-Perez and Hanson [8], using a
PTC-100 thermal cycler (MJ Research Inc., Water-
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town, MA, USA). For ESBL detection, PCRs were
performed using standard techniques [9] and
specific primers for blaTEM-type, blaSHV-type,
blaCTX-M-1, blaCTX-M-2, and blaCTX-M-9 genes.
Primers used were TEM-F (5¢-ATAAAATTCTT
GAAGACGAAA) and TEM-B (5¢-GACAGTT
ACCAATGCTTAATC) [10], SHV-F (5¢-TGGTTA
TGCGTTATATTCGCC) and SHV-B (5¢-GGTT
AGCGTTGCCAGTGCT) [11], CTX-M-1-F (5¢-GGT






respectively. The PCR-NheI method was used to
discriminate between blaSHV-type ESBL genes and
blaSHV-1 [14]. PCR amplicons from selected iso-
lates (four cefotetan-susceptible and four cefote-
tan-resistant isolates with cefotetan MICs
‡128 mg ⁄L) were purified with a QIAquick PCR
purification kit (Qiagen, Hilden, Germany) and
sequenced. The nucleotide sequences were ana-
lysed with software from the National Center for
Biotechnology Information (http://www.ncbi.
nlm.nih.gov).
All 57 K. pneumoniae isolates were found to
produce a DHA-type AmpC b-lactamase, and one
isolate co-produced a CMY-1-type enzyme. Forty-
eight isolates harboured one or more ESBL genes
(40 SHV type, 18 TEM type and seven CTX-M
type). Of the total of 57 isolates, 28 were suscept-
ible, 18 were intermediately-resistant, and 11
were resistant to cefotetan according to the
MicroScan system. The agar dilution method
indicated that 42 (73.7%) isolates were resistant,
11 (19.3%) were intermediately-resistant, and
four (7.0%) were susceptible to cefotetan. Com-
pared with the agar dilution method, the rates of
very major, minor and major errors by the
MicroScan system were 28.1% (16 ⁄ 57), 47.4%
(27 ⁄ 57) and 1.8% (1 ⁄ 57), respectively (Table 1). Of
the four isolates that were susceptible to cefotetan
according to the agar dilution method, two
showed an inoculum effect; the cefotetan MICs
were 8 and 16 mg ⁄L, respectively, but increased
to 128 mg ⁄L when an inoculum of 106 CFU ⁄mL
was used.
Although PABLs (except ACC-1) are known to
be active against cephamycins, the distribution of
cefotetan MICs among PABL producers has not,
to our knowledge, been reported previously.
According to the results of this study, although
all the DHA producers were highly resistant to
cefoxitin (MICs ‡128 mg ⁄L), 7% of DHA-type
AmpC producers were susceptible to cefotetan
according to agar dilution. Furthermore, as many
as 47.2% (25 ⁄ 53) of the DHA-type AmpC pro-
ducers determined to be insusceptible to cefotetan
according to the agar dilution method were
reported to be falsely susceptible by the Micro-
Scan system. Sequence analysis showed that all
four of the cefotetan-susceptible isolates, as well
as four other isolates that showed high cefotetan
MICs (‡128 mg ⁄L), harboured DHA-1, suggesting
that there was variability in DHA-1 expression or
that there were differences in outer-membrane
permeability. Taking into account the inducibility
of the DHA-type enzyme, there seems to be a high
risk of treatment failure if cefotetan is used, based
on its apparent in-vitro susceptibility.
In conclusion, the MicroScan WalkAway sys-
tem cannot be considered to produce reliable
cefotetan susceptibility results for DHA-produ-
cing K. pneumoniae. Therefore, considering the
increasing prevalence of PABL producers, active
surveillance of PABL enzymes will be required.
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No. (%) of isolates according to the MicroScan system
that were
Susceptible Intermediate Resistant
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R, resistant; I, intermediately-resistant; S, susceptible.
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ABSTRACT
In total, 172 isolates of Enterobacteriaceae, Acine-
tobacter spp., Pseudomonas aeruginosa and Stenotro-
phomonas maltophilia were tested for susceptibility
to colistin by agar dilution, Etest and the Vitek 2
system. Isolates with a colistin MIC £2 mg ⁄L were
considered to be susceptible. Fifty-four (31%)
Gram-negative isolates were resistant to colistin.
Categorical agreement between agar dilution and
Etest was 87%, and between agar dilution and
Vitek 2 was 82%. Based on the data obtained, the
Vitek 2 system was unreliable for detecting colis-
tin resistance, and results obtained by Etest may
require confirmation by a standard MIC suscep-
tibility testing method.
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Increasing antibiotic resistance in Gram-negative
bacilli, coupled with a shortage of new anti-
microbial agents, has led to renewed interest in
the use of polymyxins for treating multidrug-
resistant infections [1]. There are few guidelines
for antibiotic susceptibility testing of polymyxins.
The CLSI issued interpretative breakpoints for
Acinetobacter spp. only in 2005 [2], and disk
susceptibility testing generally yields poor results
with colistin [3]. Determination of colistin MICs is
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